Breckenridge Patent-Cliff Exposure & CMS Drug Spending Portfolio
Breckenridge (US): 25 reconciled FDA prescription therapies, $138.6M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 25 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $138.6M |
| 2024 Medicare Part D Spend | $109.5M |
| 2024 Medicaid Spend | $29.1M |
| California HCAI SB 17 Filings | 0 statutory filings in 2023 to 2026 panel |